As faithful predictors of response to antiangiogenic treatment in AMD have yet to be identified [30], the analysis of rs2071559 VEGFR-2 gene polymorphisms could represent a promising options for those patients treated with ranibizumab or pegaptanib. Here, KDR is linked to age-related macular degeneration.